What's Going On With Nektar Therapeutics Stock On Thursday?

Core Viewpoint - Nektar Therapeutics Inc. (NKTR) stock experienced a significant increase despite the absence of company-specific news, likely influenced by the negative performance of Sanofi SA following the COAST 1 trial results [1] Group 1: Trial Results and Comparisons - The COAST 1 trial demonstrated that amlitelimab met all primary and key secondary endpoints, showing statistically significant skin clearance and disease severity improvement compared to placebo at Week 24 for patients aged 12 years and older with moderate-to-severe atopic dermatitis [2] - Although the trial met its endpoints, the benefit magnitude of amlitelimab was below investor expectations when compared to Phase 2 benchmarks and approved treatments like Dupixent [3] - On the EASI-75 score, amlitelimab showed a 20% improvement over placebo, significantly lower than the 39% improvement reported in the previous Phase 2b study [4] Group 2: Other Relevant Studies - Nektar's ongoing Phase 2b REZOLVE-AD study of rezpegaldesleukin showed statistically significant data, with patients experiencing a 53% to 61% improvement in symptoms after 16 weeks, compared to a 31% improvement in the placebo group [4] - At week 16, a high dose of 24 µg/kg q2w achieved statistical significance on EASI-90, indicating a substantial reduction in disease severity [5] Group 3: Stock Performance - NKTR stock rose by 24.27%, reaching $35.48 during the last trading session [5]